Barriers and facilitators of the uptake of digital health technology in cardiovascular care: a systematic scoping review.

Digital health technology (DHT) has the potential to revolutionize healthcare delivery but its uptake has been low in clinical and research settings. The factors that contribute to the limited adoption of DHT, particularly in cardiovascular settings, are unclear. The objective of this review was to determine the barriers and facilitators of DHT uptake from the perspective of patients, clinicians, and researchers. We searched MEDLINE, EMBASE, and CINAHL databases for studies published from inception to May 2020 that reported barriers and/or facilitators of DHT adoption in cardiovascular care. We extracted data on study design, setting, cardiovascular condition, and type of DHT. We conducted a thematic analysis to identify barriers and facilitators of DHT uptake. The search identified 3075 unique studies, of which 29 studies met eligibility criteria. Studies employed: qualitative methods (n = 13), which included interviews and focus groups; quantitative methods (n = 5), which included surveys; or a combination of qualitative and quantitative methods (n = 11). Twenty-five studies reported patient-level barriers, most common of which were difficult-to-use technology (n=7) and a poor internet connection (n=7). Six studies reported clinician-level barriers, which included increased workload (n=4) and a lack of integration with electronic medical records (n=3).Twenty-four studies reported patient-level facilitators, which included improved communication with clinicians (n=10) and personalized technology (n=6). Four studies reported clinician-level facilitators, which included approval and organizational support from cardiology departments and/or hospitals (n=3) and technologies that improved efficiency (n=3). No studies reported researcher-level barriers or facilitators. In summary, internet access, user-friendliness, organizational support, workflow efficiency, and data integration were reported as important factors in the uptake of DHT by patients and clinicians. These factors can be considered when selecting and implementing DHTs in cardiovascular clinical settings. The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Introduction

Cardiovascular disease (CVD) places a considerable burden on patients and healthcare systems and is the leading cause of global mortality and a major cause of reduced quality of life. By 2030, the total global cost of CVD is estimated to increase from approximately $860 billion in 2010 to $1044 billion. Interventions that reduce costs attributed to CVD and improve the quality of patient care are a priority across health systems.

Digital health technology (DHT)the convergence of digital technologies with health, health care, and societyhas the potential to revolutionize CVD healthcare delivery by streamlining operations, improving patient outcomes and decreasing healthcare costs. DHT has six key applications in cardiovascular care; facilitate patient self-care through the use of self-monitoring and self-management applications on mobile devices; provide clinicians with the ability to monitor patients remotely; provide decision support to clinicians at the point of care; facilitate virtual care encounters between clinicians and patients via digital platforms; enable education of clinicians and patients via educational modules, applications, and social networking platforms; and facilitate research through recruitment, randomization, data collection, and implementation.

The SARS-CoV-2 2019 (COVID-19) pandemic has accelerated the development of DHT., Healthcare systems and policy makers have prioritized DHT as a strategy to flatten the COVID-19 curve, and to deliver care to patients in need., Despite the abundance of DHT innovations, however, uptake beyond telecare has been slow. Concerns about cost, effectiveness, and safety may be barriers, and current healthcare system processes may not readily facilitate the digital transformation. A recent position paper identified barriers impeding large-scale digital health uptake in Europe, but the barriers and facilitators of DHT adoption in cardiovascular care have not been systematically assessed.

The purpose of this systematic scoping review was to provide a comprehensive summary of barriers and facilitators of the uptake of DHT in cardiovascular care, among patients, clinicians, and researchers.

Methods and analysis

Study design

We conducted a systematic scoping review using the methodological framework developed by Arksey and OMalley: identifying the research question, identifying relevant studies, selecting studies, charting the data, collating summarizing, and reporting the results. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses modified statement for scoping reviews (PRISMA-ScR) was used to inform conduct and reporting.

The research question guiding this review was: What are the barriers and facilitators of the uptake of DHT in cardiovascular care?

Identifying relevant studies

With the aid of a professional information specialist, we conducted a systematic search of the literature for articles published in MEDLINE, EMBASE, and CINAHL. We developed our main search strategy in MEDLINE. The search strategy for MEDLINE is available in the Supplementary material online, Appendix. The search strategy was not limited by study design or language, and included the terms cardiology, digital health technology, mHealth, telemedicine, barriers, and facilitators. We supplemented the systematic literature search by hand searching the reference lists of included studies and relevant systematic reviews.

Study selection

We included studies published from inception of the databases to 7 May 2020. We included studies that focused on CVD management and reported on patient-, clinician-, and/or researcher-level barriers and/or facilitators of the uptake of DHT. For the purpose of this review, DHT was defined as a broad scope of tools that engage patients for clinical purposes; collect, organize, interpret, and use clinical data; and manage outcomes and other measures of care quality. Barriers and facilitators were defined as factors that hindered or enabled implementation of DHT in clinical practice., We excluded conference abstracts, case reports, commentaries, editorials, reviews, and protocols.

Two authors (S.W. and D.M.P.) independently screened all titles and abstracts acquired from the systematic search. Full-text versions of all studies that appeared to meet the inclusion criteria or those where there was insufficient information in the title and abstract to make a decision were obtained. S.W. and D.M.P. then independently screened all full-text versions of the studies for inclusion. Disagreements were resolved through discussion, and when required, by consulting a third author (H.G.C.V.).

Charting the data

Two authors (S.W. and D.M.P.) independently extracted the following information in duplicate: publication year, cardiovascular condition, sample size, description of the technology, method of data collection, and method of data analysis. We categorized the DHTs used in the including studies according to the American Medical Association (AMA)s classification of digital health tools (Box ). Any disagreements were resolved by discussion and consultation with a third author (H.G.C.V.).

Collating, summarizing, and reporting the findings

We followed the six-phase process developed by Braun and Clark to conduct our thematic analysis of the barriers and facilitators of DHT in CVD care: familiarizing oneself with the data, searching for the themes, reviewing themes, defining and naming themes, and producing the report.

One author (S.W.) read all of the studies, annotated them, and identified broad barrier and facilitator categories. As additional studies were read, they were mapped to previously identified categories, based on the topics discussed in them, and more categories were added as new barrier and facilitators emerged. Barrier and facilitator categories were not mutually exclusive and each study could be mapped to multiple categories based on its content. The same author (S.W.) re-read all of the studies listed under each barrier and/or facilitator category, reviewed the annotations from the previous round, and compared and contrasted the various studies findings to identify recurrent themes, discrepancies and unique findings. A second author (D.M.P.) independently performed this phase of the analysis for the studies listed under the barrier and facilitator categories. S.W. and D.M.P. then compared the analyses and discussed disagreements between them, in order to reach a consensus. Any disagreements were resolved by discussion and consultation with a third author (H.G.C.V.). We performed descriptive analyses and presented the occurrences and frequencies of the barriers and facilitators using numbers and percentages.

Results

A total of 3062 titles and abstracts produced from the systematic search and 13 hand-selected articles from the supplementary literature search were assessed for eligibility after removing duplicates. Of the 3075 articles, 2770 were excluded on the basis of title and/or abstract review. We assessed 305 full-text articles, of which 29 met eligibility criteria (; ). The references to the included studies are included in the Supplementary material online, Appendix.

PRISMA diagram of studies included in the systematic scoping review.

Characteristics of included studies

The studies in this review were published between 2008 and 2019, with a majority (n=26) published after 2014. Studies were conducted in the following countries: Australia (n=1), Canada (n=3), China (n=4), Finland (n=1), India (n=1), Ireland (n=1), Netherlands (n=1), New Zealand (n=1), Singapore (n=1), Sweden (n=2), UK (n=4), and the USA (n=9). DHTs included in the review were classified into the following AMA categories: consumer access to clinical data (n=1), patient engagement (n=15), remote monitoring and management (n=10), and tele-visits/virtual visits (n=3). Most studies included patients with CVD (n=27), heart failure (n=19), in particular; other studies included informal caregivers (n=5), healthcare clinicians (n=7), and stakeholders and/or other participants (n=3). Most of the studies (n=13) employed qualitative methods of data collection, which included interviews and focus groups, some (n=5) studies used quantitative methods, which included surveys, and the remaining studies (n=11) used a combination of qualitative and quantitative methods. The data was analysed using qualitative methods, which included content analysis (n=2), grounded theory (n=3), inductive analysis (n=1), thematic analysis (n=6), quantitative analysis (n=5), and mixed methods (n=11) ().

Patient-level barriers and facilitators

We identified 14 distinct patient-level barriers and a total of 13 facilitators (). Of the 29 included studies, 25 (86.2%) studies reported patient-level barriers. The most frequent barriers in the literature were difficulty using technology (n=7), poor internet connection (n=7) and fear of using technology (n=6), followed by feeling that the DHT delivered care was impersonal (n=5), older age (n=5) and lack of interest in technology (n=5).

Of the 29 included studies, 24 (82.7%) studies reported patient-level facilitators. The most frequent facilitator was improved connection and communication with clinicians (n=10), followed by personalized components within the technology (n=6), previous experience with technology (n=5), easy to use technology (n=5), and perceived usefulness of the technology (n=5).

Clinician-level barriers and facilitators

We identified 10 distinct clinician-level barriers and a total of 5 facilitators (). Of the 29 included studies, 6 (20.7%) studies reported clinician-level barriers. The most frequent barriers we identified were increased work and responsibilities (n=4) and unreliable technologies and/or lack of evidence supporting the use of technology (n=3), lack of integration with electronic medical records (n=3), followed by financial concerns (n=2), data privacy and security (n=2), and feeling that DHT delivered care was impersonal (n=2).

Of the 29 included studies, 4 (13.8%) studies reported clinician-level facilitators. The most frequent facilitators were approval and organizational support from cardiology departments and/or hospitals (n=3), technologies that improved efficiency (n=3), technologies that clinicians perceived as useful (n=2) and technologies that improved communication between patients and clinicians (n=2).

Researcher-level barriers and facilitators

Of the 29 included studies, no studies reported researcher-level barriers or facilitators.

Discussion

This systematic scoping review included 29 studies highlighting factors that impede or facilitate the uptake of DHT in cardiovascular care. We found that common barriers of DHT among patients included difficult-to-use technology, a poor internet connection, and fear of using technology. Common facilitators of DHT use among patients included improved connection and communication with clinicians, personalized components within the DHT, and user-friendliness. The most frequent barriers to DHT uptake by clinicians included increased work related to the technology, unreliable technology or limited evidence supporting its use, and lack of integration with electronic medical records. The most common facilitators among clinicians were institutional approval and organizational support, improved efficiency, and DHTs that were perceived to be useful. We did not identify any researcher-level barriers or facilitators of DHT.

To the best of our knowledge, this is the first systematic review to report barriers and facilitators of DHT adoption in cardiovascular care. There is limited published literature on barriers to and facilitators of DHT adoption across the medical field. A systematic review of 101 studies assessed factors influencing the uptake of DHT by clinicians across multiple diseases. Consistent with our findings, this review found that the most common facilitating factor for clinicians was perceived usefulness of DHT, and that lack of reimbursement and unreliable technologies were barriers to DHT adoption by clinicians. However, this review did not report on cardiovascular care. A recent scoping review of 36 studies assessed factors associated with DHT adoption for hypertension management. Also consistent with our findings, this review found that impersonal and difficult to use technologies were barriers to, and easy to use technologies and enhanced patient-clinician communication were facilitators of DHT uptake among patients. This review also did not report on cardiovascular care. We did not identify any publications that reported researcher-level barriers or facilitators in CVD, or any other disease state.

A number of frameworks have been developed to describe the acceptance and usage of DHTs. These frameworks include the Theory of Reasoned Action, Theory of Planned Behaviour, Technology Acceptance Model, Unified Theory of Acceptance and Use of Technology, Innovation Diffusion Theory, and the Social Cognitive Theory. A recent literature review examined the conceptual models and identified similarities between the constructs used to explain DHT adoption and use. We found that the results of our thematic analysis aligned with many of the common constructs. For example, perceived usefulness of DHTs, facilitating conditions such as internet access and technological support, and easy to use DHTs were common constructs amongst the frameworks, all of which we identified to be facilitating factors for DHT adoption. The consistencies between our findings and the pre-existing frameworks suggest that there may be common barriers and facilitators that underlie DHT uptake. Thus, targeted efforts to address these factors may improve DHT adoption, both in CVD care and across medicine as a whole.

Recommendations to increase the uptake of digital health technologies

As we navigate the COVID-19 era and beyond, urgent actions are required if we are to realize the potential of DHT., Focused strategies should be implemented to address the identified barriers and facilitators, and to promote DHT uptake in cardiovascular care ().

Design and testing

Developers should capitalize on human-centred design principles, which involve co-designing, testing and improving the technologies based on partnerships between industry, patients, and clinicians. The number of DHTs is continuously increasing, with more than 300000 health applications and more than 200 being added daily. A recent review found that most DHTs were not evaluated in randomized controlled trials, despite this methodology being the gold standard for evaluating the effectiveness of healthcare interventions. Traditionally designed randomized controlled trials are unable to match the speed of DHT development, and must evolve to efficient, pragmatic designs. Innovative observational designs, such as simulation-based research, could also facilitate quality and timely evidence. The World Health Organizations recommendations for DHTs and the United Kingdoms Institute for Health and Care Excellences Evidence Standard Framework can be used to guide the evaluation of DHTs.,

Integration

DHTs should be integrated into the current clinician workflow in order to improve access for clinicians and to effectively scale up DHTs. A literature review concluded that increased quality of care, reduced medical errors, improved patient outcomes and reduced costs were among the benefits that occur when DHT is integrated into existing workflows. Medical record systems and DHTs are often proprietary and designed to function as stand-alone systems. Clinicians are less likely to adopt DHTs that do not reduce their workload and that require them to maintain multiple systems., Without proper integration and interoperability, DHT uptake will likely be limited to clinicians who are highly motivated to adopt technologies despite the inefficiencies in workflow that come from information siloes.,

Cost and access

Efforts should be directed towards increasing access to and affordability of DHTs. Although approximately 4 billion people used the internet worldwide in 2019, internet usage was significantly greater in high-income than low- and middle-income regions (82% in Europe vs. 28% in Africa). Federal and private sectors should invest in technology and infrastructure to increase internet access, and should work on negotiating fair pricing for DHTs with vendors similar to that done for drugs and implanted devices in single-payer systems., DHTs directed at patients in the form of mobile devices, applications, or wearables should be priced fairly, and should potentially be supported through insurance plans. A survey of 253829 individuals in the USA found that higher income was a significant predictor of owning and/or utilizing DHTs compared to lower incomes. Subsidized smartphone plans and free Wi-Fi hotspots can also provide temporary solutions for accessibility barriers.

Regulation

In fee-for-service systems, clinicians should be remunerated for delivery of healthcare through DHTs. Current policies in many jurisdictions require face-to-face encounters for remuneration of consults. A survey of 106 clinicians in Canada, the USA and Ireland found that regulatory and reimbursement disincentives, including the inability to bill for services delivered via telemedicine, were among the most prominent barriers to DHT adoption. To overcome these barriers, the credentialing process for provision of DHT-related services could be made easier so that it is easy for clinicians to begin to provide care using digital health platforms. Reimbursement schemes for clinician services should not be contingent on the use of approved but expensive proprietary platforms; for example, clinicians and patients could be encouraged to use videoconferencing platforms that are Health Insurance Portability and Accountability Act (HIPAA)-compliant but available on their smart phones or existing devices instead of investing in more expensive, vendor-specific platforms. Remuneration for services should extend to the range of care options that are possible using DHTs, including but not limited to remote monitoring, telephone advice to patients or clinicians, digital consultation to patients and clinicians, and electronic communications regarding patient care. DHTs should comply with required privacy and security regulations, which include storing data in secure, firewall-protected, access-controlled locations. DHTs should also follow robust data governance frameworks that include ethical oversight and informed consent processes, data protection and sustainability of ethical data use to reduce the risks of data breach or misuse.

Institutional support

Institution should consider the long-term cost savings of DHTs through increased efficiencies and less reliance on bricks and mortar, and support their use among clinicians through training, financial investment in networks, and technical support. The long-term healthcare system benefits and cost savings from DHTs are often unclear to institutions and the upfront costs of DHTs are a barrier to uptake. A systematic review of 14 studies examined the cost-effectiveness of DHTs used in CVD care. This review found that 43% of studies reported an association between DHTs, higher quality-adjusted life years (QALYs), and cost savings. Among the remaining 57% of studies, costs were higher, but cost-effectiveness ratios were acceptable given the concomitant increase in QALYs. DHT use and mandates for DHT use are associated with increased DHT uptake. Although we did not identify the involvement of healthcare administrative staff or other stakeholders as barriers or facilitators of DHT uptake, the AMA found that engaging hospital executives and administrative staff in DHT decision processes improved DHT uptake. The engagement of administrative staff and stakeholders should be considered when implementing DHT.

Training

Training programmes for patients and clinicians can facilitate uptake of DHTs and mitigate patients uneasiness and fear around the use of DHT. An analysis of 101 older adults (65 years) enrolled in the intervention arm of a randomized controlled trial found that training programmes and continued support were crucial to patient uptake. New approaches should also be applied in modern medical education to ensure that new clinicians have the skills required to work with DHTs. A mixed methods review investigated the impact that DHT-based lessons had on medical students. The review found that students that received DHT-based lessons were more familiar with available DHTs and felt more comfortable using DHTs in their future careers compared to students who did not receive the lessons. Other training approaches should be implemented to reach practicing clinicians, such as formally requiring DHT training as part of continuing education courses or certification programmes.

Support groups and engagement of caregivers

Patients and clinicians should be provided with technology support to increase DHT uptake. The support for patients could come from formal programmes or peer support groups and e-movements. Supports to overcome language barriers may further increase the uptake of DHT. A mobile application integrated with language translating features was found to improve the quality of communication between clinicians and patients with limited English proficiency. In addition, clinicians and industry stakeholders should recognize and respect that not all patients will want to engage with DHTs. Informal caregivers and family members are important participants in healthcare, and engaging them in DHT may also be a strategic way to increase uptake among patients. An observational study of 11 patients and 5 caregivers found that caregivers who engaged in DHTs alongside patients were able to better interpret health information, advocate for quality care and better manage their patients medical care compared to caregivers who did not engage in DHTs. To further support patients, DHT could be used to supplement in-person care as part of a blended model. A narrative review found that a blended model of care between usual in-person care and DHT delivered care helped patients with chronic diseases better manage their conditions, compared to DHT delivered care alone.

Strengths and limitations

The strengths of our review included the comprehensive, evidence-based scoping review methodology, which provided the opportunity to develop an evidence base in the topic area. The screening, data extraction and thematic coding were completed independently and in duplicate, with high inter-rater agreeability, which reduced the likelihood of single reviewer bias. We utilized a broad search strategy that did not restrict studies by language or publication date, reducing the likelihood of language and selection bias. Our review also identified a significant gap in the literature, as we did not find any published primary literature on researcher-level barriers or facilitators of DHT uptake. Researcher-level barriers and facilitators of DHT uptake should be a focus of future research to further increase DHT adoption in CVD care.

Limitations of our review must be acknowledged. In keeping with the scoping review methodology,, our search and study inclusion process were broader than a standard systematic review but also more limited in terms of databases. There is a possibility that eligible studies may have been missed. To mitigate this risk, we hand searched the reference lists of all articles that underwent full text screening. Ascertaining barriers and facilitators of DHTs was not the primary aim of all of our included studies. We used our best judgement to identify and classify themes but recognize that our personal biases may have influenced the thematic analysis. The DHTs described in the included studies were multifaceted. This may have led to misclassification errors in the thematic analysis. However, we anticipate this error being small as all stages of the review were completed in duplicate and consensus was reached for each classification. Lastly, we did not include grey literature, which may have biased our results as the field of DHT is moving rapidly and novel interventions may not have been published. We recommend that researchers aiming to build on this work use a wider range of databases, search unpublished and grey literature and incorporate direct feedback from relevant stakeholders, researchers, clinicians, and patient partners.

Conclusion

DHT has the potential to revolutionize CVD healthcare delivery. Our results demonstrate that there are a multitude of barriers and facilitators to the uptake of DHT in cardiovascular care. The findings of this study can be used to inform and guide clinicians, and stakeholders who wish to develop and implement DHTs that meet the needs of clinicians and patients in the COVID-19 era and beyond.

Supplementary material

Supplementary material is available at European Heart Journal Digital Health online.

Funding

H.G.C.V. receives research funding from the Canadian Institutes of Health Research and research salary support from McMaster University Department of Medicine and Women As One Escalator Award.

Data availability

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

Conflict of interest: none declared.

Click here for additional data file.

Box 1

American Medical Associations classification of digital health tools

Remote monitoring for efficiency:16 Smart versions of common clinical devices such as thermometers, blood pressure cuffs, and scales that automatically record readings in the patient record, so you do not have to type it.

Remote monitoring and management for improved care: Apps and devices for use by chronic disease patients for daily measurement of vital signs such as weight, blood pressure, blood glucose, etc. Readings are visible to patients and transmitted to the physicians office. Alerts are generated as appropriate for missing or out of range readings.

Clinical decision support: Modules used in conjunction with the EHR or apps that integrate with the EHR that highlight potentially significant changes in patient data (e.g. gain or loss of weight, change in blood chemistry).

Patient engagement: Solutions to promote patient wellness and active participation in their care for chronic diseases (e.g. adherence to treatment regimens).

Tele-visits/virtual visits: An audio/video connection used to see patients remotely (i.e. simple acute illness, adjusting therapy, etc.).

Point of care/workflow enhancement: Communication and sharing of electronic clinical data to consult with specialists, make referrals and/or transitions of care.

Consumer access to clinical data: Secure access allowing patients to view clinical information such as routine lab results, receive appointment reminders and treatment prompts, and to ask for prescription refills, appointments and to speak with their physician.

Table 1

Characteristics of included studies (n=29)

Reference and country	Study period	Digital health tool	Description of tool	Participants	Method of data collection	Analysis
Allemann 2019 (Sweden)	20152017	Tele-visits/virtual visits	Information communication technologies designed to support family members in caring for patients.	Family members of patients with heart failure who received care from a heart function clinic (n=8)	Focus groups	Content analysis
Alnosayan 2017 (USA)	2012	Remote monitoring and management	A mHealth system which includes a Bluetooth-enabled blood pressure monitor, weight scale, glucose metre, and a mobile phone loaded with the MyHeart application programmed to alert clinicians upon patient decompensation.	Patients with heart failure who had recently been discharged from the hospital (n=8) and nurses who worked in heart failure clinics (n=6)	Focus groups	Grounded theory
Ancker 2015 (USA)	2015	Patient engagement	Personal health information tracking facilitated through digital technology to monitor patients health conditions.	Patients with at least one chronic medical condition (n=22) and clinicians from internal medicine clinics (n=7)	Semi-structured interviews	Grounded theory and thematic analysis
Anttilla 2019 (Finland)	20152016	Tele-visits/virtual visits	A remote cardiac rehabilitation programme delivered through video conferencing software.	Patients who had undergone coronary angioplasty or coronary artery bypass (n=39) and were prescribed cardiac rehabilitation	Focus groups	Grounded theory
Buck 2017 (USA)	2015	Patient engagement	An internet-based tablet where participants recorded their daily medication intake, weight, and time spent exercising and could access disease-specific educational videos.	Patients with heart failure (n=12) who had recently been discharged from the hospital	Semi-structured interviews	Inductive analysis
Cajita 2017 (USA)	2016	Remote monitoring and management	A mHealth monitoring system composed of a weight scale, blood pressure monitor, pulse oximeter, and a mobile device.	Patients with heart failure (n=129) who had recently been discharged from the hospital	Survey	Quantitative analysis
Chantler 2016 (UK)	20132014	Remote monitoring and management	A mHealth monitoring system that included a tablet and a Bluetooth enabled blood pressure monitor and weight scale.	Patients with heart failure (n=45)	Semi-structured interviews	Thematic analysis
Chen 2018 (China)	2015	Patient engagement	A mobile application that administered messages to patients to improve medication adherence and encourage lifestyle modifications.	Patients with myocardial infarction or coronary heart disease (n=24) and physicians who cared for cardiovascular disease patients (n=10)	Surveys, focus groups and interviews	Quantitative and thematic analysis
Dang 2017 (USA)	2011	Patient engagement	A mobile phone monitoring system facilitated through website-based messaging.	Patients with heart failure (n=34) who attended a heart failure clinic	Surveys and interviews	Quantitative and thematic analysis
Guo 2019 (China)	2017	Remote monitoring and management	A tablet-based platform that collected and integrated patient data from monitoring devices, electronic health records, and laboratory investigations with secure messaging and video conferencing capabilities.	Patients with heart failure (n=66) who attended a specialty cardiology clinic and physicians (n=23)	Surveys and interviews	Quantitative and thematic analyses
Haldane 2019 (Singapore)	Not reported	Patient engagement	Mobile text messages to promote medication adherence.	Patients with coronary artery disease, ischaemic stroke, peripheral artery disease, or atherosclerotic aortic disease (n=20)	Surveys and semi-structured interviews	Quantitative and constant comparison analyses
Holender 2018 (UK)	2015	Patient engagement	Mobile phones, smart watches, and ingestible sensor systems to monitor medication adherence.	Patients (n=12) taking cardiovascular medications	Focus groups	Thematic analysis
Hunting 2015 (Canada)	20122014	Remote monitoring and management	Telehomecare programme to increase self-management skills and to improve the monitoring of patients via remote health status monitoring.	Patients (n=39) with heart failure and/or informal caregivers, nurses (n=16), physicians (n=7), technicians (n=2), administrators (n=12), and decision makers (n=13)	Semi-structured interviews, ethnographic observations and document review	Grounded theory
Jiang 2019 (China)	2016	Patient engagement	A mobile health system to support disease-specific self-management.	Patients (n=231) taking long-term medications for hypertension, coronary heart disease, heart failure, or arrhythmia	Survey	Quantitative analysis
Kerr 2010 (UK)	Not reported	Patient engagement	A web-based platform that provided educational information, behaviour change support, and peer and expert support.	Patients with coronary heart disease (n=168)	Surveys and semi-structured interviews	Quantitative and thematic analyses
Lefler 2018 (USA)	Not reported	Remote monitoring and management	A mHealth monitoring system that included a tablet and a Bluetooth-enabled blood pressure monitor and weight scale to provide real-time monitoring and alert clinicians upon decompensation.	Patients with heart failure (n=21) who attended specialist cardiology clinics	Surveys and semi-structured interviews	Quantitative and content analyses
Li 2017 (China)	20112013	Patient engagement	A short message service to encourage disease-specific self-management.	Patients admitted to the hospital with heart failure (n=540)	Survey	Quantitative analysis
Nahm 2008 (USA)	2006	Patient engagement	A web-based eHealth management programme to support self-management.	Patients with heart failure (n=44)	Survey	Quantitative analysis
Nguyen 2017 (Canada)	2014	Patient engagement	Digital health technology to promote self-care after hospital discharge.	Patients with heart failure (n=18) who attended a heart function clinic after being discharged from the hospital and their informal caregivers (n=10)	Surveys and semi-structured interviews	Quantitative and thematic analyses
Pfaeffli Dale 2015 (New Zealand)	20112012	Patient engagement	Mobile text messages and an interactive website with exercise prescriptions tailored to participants fitness level.	Patients with ischaemic heart disease (n=17)	Surveys and interviews	Quantitative and thematic analyses
Pekmezaris 2016 (USA)	Not reported	Tele-visits/virtual visits	A telemonitoring system that combined monitoring of patients vital signs through a glucometer, blood pressure monitor, weight scale, pulse oximeter, and stethoscope with video visits from clinicians.	Patients with heart failure, caregivers, clinicians, and health policy representatives (n=14)	Focus groups	Thematic analysis
Rief 2017 (USA)	20102011	Consumer access to clinical data	A patient accessible personal health record system that included medication lists, information about allergies and immunizations, medical histories, laboratory results, health reminders, and secure messaging.	Patients with coronary artery disease, heart failure, hypertension, or hyperlipidaemia (n=41)	Focus groups	Thematic analysis
Sanders 2012 (UK)	20082009	Remote monitoring and management	A telehealth monitoring system that included a blood pressure monitor, glucometer, pulse oximeter, and weight scale and alerted clinicians upon patient decompensation.	Patients with diabetes, chronic obstructive pulmonary disease, or heart failure (n=22)	Semi-structured interviews	Thematic analysis, grounded theory and constant comparison
Smith 2015 (India)	Not reported	Remote monitoring and management	The expanded use of mobile phones to improve cardiovascular disease management.	Accredited social health activists (n=5), physicians (n=5), and patients with cardiovascular disease (n=5)	Semi-structured interviews	Thematic analysis
Treskes 2019 (Netherlands)	2017	Remote monitoring and management	The broad use of information technology to deliver health care in cardiology.	Physicians (n=255) specializing in cardiology	Survey	Quantitative analysis
Wallin 2018 (Sweden)	20152016	Patient engagement	An internet-based cognitive behavioural therapy programme that included educational and therapeutic modules and secure messaging capabilities aimed to improve depression and anxiety symptoms.	Patients who were recently hospitalized for a myocardial infarction (n=117) and were experiencing depression and/or anxiety	Semi-structured interviews	Content analysis
Walsh 2018 (Ireland)	20162017	Patient engagement	An internet-enabled, sensor-based home exercise cardiac rehabilitation programme to encourage exercise participation and self-management.	Patients with cardiovascular disease (n=33) and healthcare stakeholders (n=21)	Semi-structured interviews	Thematic analysis
Ware 2019 (Canada)	20162018	Remote monitoring and management	A mobile application where patients recorded their weight, blood pressure, heart rate, and symptoms to generate an algorithm that alerted clinicians upon decompensation.	Patients with heart failure (n=24) who attended a heart function clinic	Surveys and semi-structured interviews	Quantitative and thematic analyses
Woods 2019 (Australia)	Not reported	Patient engagement	A mobile application designed to encourage self-management that included educational material, reminders and symptom tracking.	Patients with heart failure (n=8) who had recently been discharged from the hospital	Surveys and semi-structured interviews	Quantitative and thematic analyses

Table 2

Summary of characteristics of included studies (n=29)

	Number of studies (%)
Country
Australia	1 (3.4)
Canada	3 (10.3)
China	4 (13.8)
Finland	1 (3.4)
India	1 (3.4)
Ireland	1 (3.4)
Netherlands	1 (3.4)
New Zealand	1 (3.4)
Singapore	1 (3.4)
Sweden	2 (6.9)
UK	4 (13.8)
USA	9 (31.0)
Participants
Caregivers	5 (17.2)
Patients	27 (93.1)
Clinicians	7 (24.1)
Stakeholders and other	3 (10.3)
Digital health tool
Consumer access to clinical data	1 (3.4)
Patient engagement	15 (51.7)
Remote monitoring and management	10 (34.5)
Tele-visits/virtual visits	3 (10.3)
Cardiovascular condition
Arrhythmia	1 (3.4)
Atherosclerotic aortic disease	1 (3.4)
Coronary artery bypass graft	1 (3.4)
Coronary artery disease	6 (20.7)
Heart failure	19 (65.5)
Myocardial infarction	2 (6.9)
Unspecified	5 (17.2)
Data collection
Focus groups	6 (20.7)
Interviews	7 (24.1)
Mixed methods	11 (37.9)
Surveys	5 (17.2)
Analysis method
Content analysis	2 (6.9)
Grounded theory	3 (10.3)
Inductive analysis	1 (3.4)
Mixed methods analysis	12 (41.4)
Quantitative analysis	5 (17.2)
Thematic analysis	6 (20.7)
Year of publication
2008	1 (3.4)
2010	1 (3.4)
2012	1 (3.4)
2015	4 (13.8)
2016	2 (6.9)
2017	7 (24.1)
2018	5 (17.2)
2019	8 (27.6)

Table 3

Patient-level barriers and facilitators of the uptake of digital health technology (29 studies)

	Studies, n (%)
Facilitators
Improved connection and communication with clinicians	10 (34.5)
Personalized components	6 (20.7)
Easy to use technology	5 (17.2)
Previous experience with technology	5 (17.2)
Perceived usefulness	5 (17.2)
Empowerment	5 (17.2)
Education and training sessions	3 (10.3)
Support from family and/or caregivers	2 (6.9)
Home internet access	2 (6.9)
Technological support	2 (6.9)
Willingness to learn	1 (3.4)
Higher education	1 (3.4)
Improved sense of security	1 (3.4)
Barriers
Difficult to use technology	7 (24.1)
Poor internet connection	7 (24.1)
Fear of using technology	6 (20.7)
Impersonal care delivery	5 (17.2)
Older age	5 (17.2)
Lack of interest in technology	5 (17.2)
Cognitive impairment	4 (13.8)
Technical problems	4 (13.8)
Time consuming	4 (13.8)
Emotional and/or moral implications	3 (10.3)
Financial concerns	3 (10.3)
Language barriers	3 (10.3)
Anxiety and/or other mental health conditions	1 (3.4)
Mobility limitations	1 (3.4)

Table 4

Clinician-level barriers and facilitators of the uptake of digital health technology (29 studies)

	Studies, n (%)
Facilitators
Approval and organizational support from cardiology departments and/or hospitals	3 (10.3)
Improved efficiency	3 (10.3)
Perceived usefulness	2 (6.9)
Increased communication with patients and clinicians	2 (6.9)
Training programmes	1 (3.4)
Barriers
Increased work and responsibilities	4 (13.8)
Unreliable technologies and/or lack of evidence supporting the use of technology technology	3 (10.3)
Lack of integration with electronic medical records	3 (10.3)
Data privacy and security concerns	2 (6.9)
Financial concerns	2 (6.9)
Impersonal care delivery	2 (6.9)
Lack of customizable features	1 (3.4)
Negative pressure from department and/or hospitals	1 (3.4)
Healthcare reimbursement issues	1 (3.4)
Time consuming	1 (3.4)

Table 5

Recommendations to increase the uptake of digital health technology in cardiovascular care

Design	Developers should capitalize on human-centred design principles and engage patients, clinicians and stakeholders throughout the entirety of the technology development process.
Testing	Digital health technologies should be tested and validated with cardiology patients and clinicians. Digital health technologies should be routinely evaluated to account for data errors as a result of user error and/or misuse. Evaluation of all digital health technologies should adhere to quality improvement guidelines.
Data privacy and security	Digital health technologies should comply with all required data governance, privacy, and security regulations.
Personalized care	Digital health technology should supplement in-person care (blended model).
Integration	Digital health technologies should be integrated with electronic medical records and existing health system processes.
Cost and access	Digital health technologies should be tailored to the target regions. Federal and private sectors should invest in technology and infrastructure to increase internet/broadband access. Digital health technologies should be priced fairly to the target users. Patients should be able to claim digital health technologies through insurance plans. Subsidized smartphone plans, free Wi-Fi hotspots and technology renting programmes should be available for those who need it. Automated applications and devices that do not require continuous internet access should be implemented in regions without sufficient infrastructure and funds to support cellular and data coverage.
Regulations	Regulatory models should be developed to permit clinicians to obtain credentialing for digital health technologies. Regulations and guidelines should be established to define and communicate responsibilities and liabilities to technology vendors, clinicians and patients. All digital health technologies should be regulated and certified.
Reimbursement	Clinicians should receive reimbursement for using digital health technologies. Guidelines, policies and procedures for using and reimbursing digital health technologies should be implemented.
Departments and institutions	Departments and institutions should support and encourage the use of digital health technologies. Performance incentives and mandates should be implemented to encourage digital health technology uptake.
Patient supports	Patients should receive education on the benefits of digital health technologies. Patients should be encouraged to participate in e-patient movements and advocacy. Patients should be provided with accessible translating features and accessible technologies to overcome language barriers and disabilities. Family members and informal caregivers should engage in digital health technologies with the patients.
Training	Patients should be provided training when prescribed digital health technology. Medical students should receive education on digital health technology as part of their medical school curriculum. Practicing clinicians should be required to complete continuing education programmes or certification courses in digital health technology.
Technology support	Technology supports should be provided for both patients and clinicians.